Strategic investments Identify co-investment and syndication opportunities with Samsara BioCapital as they participate in late-stage rounds and lead or co-lead with prominent firms, presenting a pathway for joint deal flow and expanded portfolio access.

Therapeutic focus Target biotech companies in kidney disease, ocular diseases, cancer, autoimmune conditions, and brain-permeant CNS therapies given Samsara's active and diverse investment patterns across modalities, enabling tailored outreach to relevant scientists and founders.

Clinical-stage emphasis Prioritize startups with strong clinical-stage pipelines or Phase 1/2 programs (e.g., brain-penetrant inhibitors, ALS-related programs, ocular therapeutics) as they align with Samsara’s historical financing style and likely appetite for later-stage follow-on rounds.

Global collaboration Leverage the firm’s international portfolio activity and collaborations with notable co-investors to propose cross-border partnerships, licensing, or co-development structures that fit Samsara’s growth and risk-sharing approach.

Funding velocity Offer compelling funding stories with clear use of proceeds, milestone-driven milestones, and evidence of meaningful capital efficiency to match Samsara’s demonstrated capacity to deploy multi-million dollar Series A or follow-on investments when promising data emerges.